Population-based study of cardiovascular mortality among patients with prostate cancer treated with radical external beam radiation therapy with and without adjuvant androgen deprivation therapy at the British Columbia cancer agency

International Journal of Radiation Oncology Biology Physics

Volumn 80, Issue 3, 2011, Pages 742-750

  Kim, Julian ^a   Vaid, Moninder ^a   Tyldesley, Scott ^a,b   Woods, Ryan ^b   Pickles, Tom ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

adverse effects; Androgen deprivation therapy; cardiovascular mortality; prostate neoplasms; radiotherapy

Indexed keywords

ADVERSE EFFECT; ANDROGEN DEPRIVATION THERAPY; BRITISH COLUMBIA; CARDIOVASCULAR MORTALITY; COMPETING RISKS; CONFIDENCE INTERVAL; CUMULATIVE INCIDENCE; CURATIVE INTENT; EXTERNAL BEAM RADIATION THERAPY; MORTALITY RATE; PROSTATE CANCERS; PROSTATE NEOPLASMS; RISK FACTORS;

DISEASES; MULTIVARIANT ANALYSIS; PATIENT MONITORING; RADIATION EFFECTS; RISK ANALYSIS; RISK ASSESSMENT;

RADIOTHERAPY;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER REGISTRY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DATA BASE; EXTERNAL BEAM RADIOTHERAPY; HEALTH SERVICE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RISK ASSESSMENT; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BRITISH COLUMBIA; CANCER CARE FACILITIES; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RISK FACTORS; TIME FACTORS;

EID: 79957561051     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.03.018     Document Type: Article

References (20)

1. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
2. A.V. D'Amico, J. Manola, and M. Loffredo 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial J Am Med Assoc 292 2004 821 827 (Pubitemid 39079668)
3. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
4. M.J. Barry, M.A. Delorenzo, and E.S. Walker-Corkery The rising prevalence of androgen deprivation among older american men since the advent of prostate-specific antigen testing: A population-based cohort study BJU Int 98 2006 973 978 (Pubitemid 44536442)
5. M.R. Smith, H. Lee, and F. McGovern Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome Cancer 112 2008 2188 2194 (Pubitemid 351628628)
6. M. Braga-Basaria, A.S. Dobs, and D.C. Muller Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy J Clin Oncol 24 2006 3979 3983 (Pubitemid 46630747)
7. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and CV disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456 (Pubitemid 46630983)
8. S.M. Alibhai, M. Duong-Hua, and R. Sutradhar Impact of androgen deprivation therapy on CV disease and diabetes J Clin Oncol 27 2009 3452 3458
9. J.A. Efstathiou, K. Bae, and W.U. Shipley Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02 Eur Urol 54 2008 816 823
10. J.A. Efstathiou, K. Bae, and W.U. Shipley Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31 J Clin Oncol 27 2009 92 99
11. M. Roach 3rd, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591 (Pubitemid 351264352)
12. A.V. D'Amico, J.W. Denham, and J. Crook Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425 (Pubitemid 46999213)
13. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496
14. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation J Chron Dis 40 1987 373 383 (Pubitemid 17055592)
15. H. Lukka, P. Warde, and T. Pickles Controversies in prostate cancer radiotherapy: Consensus development Can J Urol 8 2001 1314 1322
16. C.S. Saigal, J.L. Gore, and T.L. Krupski Androgen deprivation therapy increases CV morbidity in men with prostate cancer Cancer 110 2007 1493 1500 (Pubitemid 47463063)
17. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and CV disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456 (Pubitemid 46630983)
18. H.K. Tsai, A.V. D'Amico, and N. Sadetsky Androgen deprivation therapy for localized prostate cancer and the risk of CV mortality J Natl Cancer Inst 99 2007 1516 1524 (Pubitemid 351767235)
19. A. Nanda, M.H. Chen, and M.H. Braccioforte Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction J Am Med Assoc 302 2009 866 873
20. P.C. Albertsen, J.A. Hanley, and J. Fine 20-Year outcomes following conservative management of clinically localized prostate cancer J Am Med Assoc 293 2005 2095 2101 (Pubitemid 40617061)